

Medical and Behavioral Health Policy Activity

Policies Effective: July 1, 2024 Notification Posted: May 1, 2024

Policies Developed

None

Policies Revised

- **Fecal Microbiota, II-198**

NOTE: When Vowst™ will be used for the prevention of recurrent CDI, refer to the appropriate pharmacy benefit plan.

I. Fecal Microbiota Transplantation for Treatment of rCDI

Fecal microbiota transplantation may be considered **MEDICALLY NECESSARY AND APPROPRIATE** for treatment of patients with recurrent Clostridioides (formerly Clostridium) difficile infection when BOTH of the following criteria are met:

- At least 3 episodes of infection (at least 2 recurrences); **AND**
- Episodes are refractory to appropriate antibiotic regimens, including at least ONE of the following:
 - Oral vancomycin therapy using a tapered and pulsed regimen; or
 - Standard course of oral vancomycin followed by rifaximin; or
 - Fidaxomicin;**AND**
- rCDI is confirmed by, or in consultation with, a gastroenterologist or infectious disease specialist.

II. Fecal Microbiota (Rebyota™) for Prevention of rCDI

Fecal microbiota (Rebyota™) may be considered **MEDICALLY NECESSARY AND APPROPRIATE** for the prevention of recurrence of Clostridioides difficile infection when ALL of the following criteria are met:

- Age 18 years or older; **AND**
- Diagnosis of recurrent Clostridioides difficile infection (rCDI); **AND**
- One or more recurrences after a primary episode of CDI; **AND**
- Currently taking antibiotics to control rCDI symptoms; **AND**
- Prescribed by, or in consultation with, a gastroenterologist or infectious disease specialist.

III. Experimental/Investigative Uses

Fecal microbiota transplantation and fecal microbiota (Rebyota™) are considered **EXPERIMENTAL/INVESTIGATIVE** for all other indications due to a lack of clinical evidence demonstrating an impact on improved health outcomes.

Policies Delegated to eviCore

None

Policies Inactivated

None